UNASSIGNED: Patients with < 4 primary or metastatic liver tumors with diameters ≤ 50 mm and expected to have a respiratory motion of ≥ 10 mm were eligible. The prescribed dose was 40 Gy in five fractions. The primary endpoint was local control (LC) at 2 years. The secondary endpoints were overall survival (OS), progression-free survival (PFS), treatment-related toxicity, and tracking accuracy.
UNASSIGNED: Between September 2015 and March 2019, 48 patients (48 lesions) with a median age of 74 years were enrolled from four institutions. Of these, 39 were diagnosed with hepatocellular carcinoma and nine with metastatic liver cancer. The median tumor diameter was 17.5 mm. DTT-SBRT was successfully performed in all patients; the median treatment time was 28 min/fraction. The median follow-up period was 36.5 months. The 2-year LC, OS, and PFS rates were 98.0 %, 88.8 %, and 55.1 %, respectively. Disease progression was observed in 33 (68.8 %) patients. One patient (0.2 %) had local recurrence, 31 (64.6 %) developed new hepatic lesions outside the irradiation field, and nine (18.8 %) had distant metastases (including overlap). Grade 3 late adverse events were observed in seven patients (14.5 %). No grade 4 or 5 treatment-related toxicity was observed. The median tracking accuracy was 2.9 mm.
UNASSIGNED: Employing DTT-SBRT to treat liver tumors results in excellent LC with acceptable adverse-event incidence.
UNASSIGNED:患有<4例原发性或转移性肝肿瘤且直径≤50mm且预期呼吸运动≥10mm的患者符合条件。
UNASSIGNED:在2015年9月至2019年3月之间,来自四个机构的48例患者(48个病变)中位年龄为74岁。
UNASSIGNED:使用DTT-SBRT治疗肝脏肿瘤可产生优异的LC,不良事件发生率可接受。